Compared with non-targeted vaccines, vaccines that target tumor draining lymph nodes (tdLN) can regress tumors and retain a higher host survival rate, because they induce intense cytotoxic CD8 + T cells reactions (87). This evidence concerns the gene CD8A and neoplasm.